Journal ArticleDOI
Acute and Longer- Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report
A. John Rush,Madhukar H. Trivedi,Stephen R. Wisniewski,Andrew A. Nierenberg,Jonathan W. Stewart,Diane Warden,George Niederehe,Michael E. Thase,Philip W. Lavori,Barry D. Lebowitz,Patrick J. McGrath,Jerrold F. Rosenbaum,Harold A. Sackeim,David J. Kupfer,James F. Luther,Maurizio Fava +15 more
Reads0
Chats0
TLDR
The acute and longer-term treatment outcomes associated with each of four successive steps in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial are described and compared.Abstract:
Objective: This report describes the participants and compares the acute and longer-term treatment outcomes associated with each of four successive steps in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial. Method: A broadly representative adult outpatient sample with nonpsychotic major depressive disorder received one (N=3,671) to four (N=123) successive acute treatment steps. Those not achieving remission with or unable to tolerate a treatment step were encouraged to move to the next step. Those with an acceptable benefit, preferably symptom remission, from any particular step could enter a 12-month naturalistic follow-up phase. A score of ≤5 on the Quick Inventory of Depressive Symptomatology–Self-Report (QIDS-SR 16 ) (equivalent to ≤7 on the 17-item Hamilton Rating Scale for Depression [HRSD 17 ]) defined remission; a QIDS-SR 16 total score of ≥11 (HRSD 17 ≥14) defined relapse. Results: The QIDS-SR 16 remission rates were 36.8%, 30.6%, 13.7%, and 13.0% for the first, second, t...read more
Citations
More filters
Journal ArticleDOI
Rare Copy Number Variation in Treatment-Resistant Major Depressive Disorder
Colm O'Dushlaine,Stephan Ripke,Douglas M. Ruderfer,Steven P. Hamilton,Maurizio Fava,Dan V. Iosifescu,Isaac S. Kohane,Susanne Churchill,Victor M. Castro,Caitlin C. Clements,Sarah R. Blumenthal,Shawn N. Murphy,Jordan W. Smoller,Jordan W. Smoller,Roy H. Perlis,Roy H. Perlis +15 more
TL;DR: Contribution of rare CNVs to TRD appears to be modest, individually or in aggregate, and the electronic health record-based methodology demonstrated here should facilitate collection of larger TRD cohorts necessary to further characterize these effects.
Journal ArticleDOI
Esketamine for treatment resistant depression
Jennifer Swainson,Jennifer Swainson,Rejish K. Thomas,Rejish K. Thomas,Shaina Archer,Carson Chrenek,Carson Chrenek,Mary-Anne B. MacKay,Glen B. Baker,Serdar M. Dursun,Serdar M. Dursun,Larry J. Klassen,Pratap Chokka,Pratap Chokka,Michael L Demas,Michael L Demas +15 more
TL;DR: Both esketamine’s approval for use in TRD and longer-term safety data may position it preferentially above racemic ketamine, although factors such as cost and monitoring requirements may limit its use.
Journal ArticleDOI
The sertraline versus electrical current therapy for treating depression clinical study (select-TDCS): results of the crossover and follow-up phases.
Leandro Valiengo,Isabela M. Benseñor,Alessandra C. Goulart,B S Janaina Farias de Oliveira,B S Tamires Araujo Zanao,Paulo S. Boggio,Paulo A. Lotufo,Felipe Fregni,Andre R. Brunoni +8 more
TL;DR: TDCS effects during phases II and III of the SELECT‐TDCS trial are described, finding that tDCS is effective for the acute episode.
Journal ArticleDOI
Incomplete response in late-life depression: getting to remission
Eric J. Lenze,Meera Sheffrin,Henry C. Driscoll,Benoit H. Mulsant,Bruce G. Pollock,Mary Amanda Dew,Frank Lotrich,Bernie Devlin,Robert R. Bies,Charles F. Reynolds +9 more
TL;DR: Evidence is needed to support personalized treatment in late-life depression by testing the moderating role of clinical (eg, comorbid anxiety, medical burden, and executive impairment) and genetic and genetic variables, while also controlling for variability in drug exposure.
Journal ArticleDOI
Neurobehavioral comorbidities of epilepsy: Role of inflammation
TL;DR: It appears likely that priming of the brain due to early inflammation could provide a means by which subsequent inflammatory processes associated with epilepsy, ASD, and depression may lead to comorbidity.
References
More filters
Journal ArticleDOI
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice
Madhukar H. Trivedi,A. John Rush,Stephen R. Wisniewski,Andrew A. Nierenberg,Diane Warden,Louise Ritz,Grayson Norquist,Robert H Howland,Barry D. Lebowitz,Patrick J. McGrath,Kathy Shores-Wilson,Melanie M. Biggs,Goundappa K. Balasubramani,Maurizio Fava +13 more
TL;DR: The response and remission rates in this highly generalizable sample with substantial axis I and axis III comorbidity closely resemble those seen in 8-week efficacy trials.
Journal ArticleDOI
The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression.
A. John Rush,Madhukar H. Trivedi,Hicham M. Ibrahim,Thomas J. Carmody,Bruce A. Arnow,Daniel N. Klein,John C. Markowitz,Philip T. Ninan,Susan G. Kornstein,Rachel Manber,Michael E. Thase,James H. Kocsis,Martin B. Keller +12 more
TL;DR: The QIDS-SR(16) has highly acceptable psychometric properties, which supports the usefulness of this brief rating of depressive symptom severity in both clinical and research settings.
Journal ArticleDOI
Cross-Validation of Item Selection and Scoring for the SF-12 Health Survey in Nine Countries: Results from the IQOLA Project
Barbara Gandek,John E. Ware,Neil K. Aaronson,Giovanni Apolone,Jakob B. Bjorner,John Brazier,Monika Bullinger,Stein Kaasa,Alain Leplège,Luis Prieto,Marianne Sullivan +10 more
TL;DR: In this article, the authors compared the SF-12 and SF-36 summary measures in nine European countries (Denmark, France, Germany, Italy, Netherlands, Norway, Spain, Sweden, and the United Kingdom).
Journal ArticleDOI
Cumulative illness rating scale.
TL;DR: A Cumulative Illness Rating Scale, designed to meet the need for a brief, comprehensive and reliable instrument for assessing physical impairment, has been developed and tested and is well suited to a variety of research uses.
Journal ArticleDOI
The Inventory of Depressive Symptomatology (IDS): Psychometric properties.
TL;DR: Analysis of sensitivity to change in symptom severity in an open-label trial of fluoxetine showed that the IDs-C and IDS-SR were highly related to the 17-item Hamilton Rating Scale for Depression.